期刊文献+

SRT1720对DOCA盐敏感性高血压大鼠的治疗作用

Therapeutic effect of SRT1720 on DOCA salt-sensitive hypertensive rats
下载PDF
导出
摘要 目的:观察沉默信息调节因子2相关酶1(Sirtuin1,SIRT1)激活剂SRT1720对醋酸去氧皮质酮(DOCA)盐敏感性高血压大鼠(DHR)血压的调控作用。方法:28只SD大鼠行左肾切除后随机分为3组:对照组、模型组、SRT1720治疗组。对照组(n=8):饮自来水;模型组(n=10)和SRT1720治疗组(n=10):将200 mg/kg DOCA与硅胶制成的橡皮介质放置在大鼠两侧肩胛骨之间的皮下,并予1%Na Cl饮水。SRT1720治疗组给予100 mg/(kg·d)灌胃。每周测收缩压1次。4周后处死,处死前检测中心动脉压及大鼠脉搏波速度,处死后取胸主动脉分别作HE染色观察主动脉厚度与血管口径变化。结果:模型组大鼠收缩压、中心动脉压、脉搏波速度明显增高,HE染色示血管平滑肌细胞(VSMC)明显肥大,弹力纤维层增厚,主动脉厚度显著增厚,而血管内径则明显下降。SRT1720治疗组大鼠收缩压、中心动脉压及脉搏波速度均较模型组显著下降。同时,SRT1720治疗后血管壁的病理改变明显减轻,血管平滑肌细胞肥大受到显著抑制,主动脉厚度显著下降,而血管内径明显增加。结论:SRT1720可通过抑制血管平滑肌细胞肥大,降低主动脉厚度,从而扩大血管内径,降低中心动脉压及收缩压。 Objective:To investigate the role of silent mating type information regulation 2 homolong1(SIRT1)activator SRT1720 in deoxycorticosterone acetate(DOCA)salt-sensitive hypertensive rats(DHR). Methods:A total of 28 male Sprague-Dawley rats underwent left nephrectomy were randomly divided into three groups:control group,model group,and SRT1720 treatment group. Control group(n=8):drinking water; model group(n=10)and SRT1720 treatment group(n=10):DOCA and silicone rubber medium at the concentration of 200 mg/kg was placed subcutaneously in rats on both sides of the scapula and given 1% Na Cl drinking water. SRT1720 treatment group was given intragastric administration of SRT1720 for 4 weeks at the concentration of 100 mg/(kg·d). Systolic blood pressure(SBP)was measured once a week. After 4 weeks,central arterial pressure and pulse wave velocity(PWV)were monitored,and then rats were sacrificed. Thoracia aorta was taken for HE staining to observe the thickness and vascular caliber change. Results:In model group,SBP,central aortic pressure and PWV were significantly increased. HE staining showed marked vascular smooth muscle cell(VSMC)hypertrophy,and marked thickening of elastic fiber layer and aortic media,but a significantly decreasing in vessel diameter.Meanwhile,SRT1720 treatment group reversed these changes. Conclusion:SRT1720 could inhibit VSMC hypertrophy,reduce aortic media thickness,thereby expend blood vessel diameter,and reduce central arterial pressure and peripheral blood pressure in DOCA salt-sensitive hypertensive rats.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2016年第8期960-963,共4页 Journal of Nanjing Medical University(Natural Sciences)
基金 国家973项目(2013CB530604)
关键词 SRT1720 高血压 醋酸去氧皮质酮 SRT1720 hypertension deoxycorticosterone acetate
  • 相关文献

参考文献22

  • 1Ahad A, Aqil M, Kohli K, et al. Role of novel terpenes in transcutaneous permeation of valsartan: effectiveness and mechanism of action[J]. Drug Dev Ind Pharm, 2011,37 (5):583-596.
  • 2Campbell N, Young ER, Drouin D, et al. A framework for discussion on how to improve prevention, manage- ment, and control of hypertension in Canada[J]. Can J Cardiol, 2012,28 (3) : 262-269.
  • 3Barri YM. Hypertension and kidney disease: a deadly connection [J]. Curr Cardiol Rep, 2006,8 (6) : 411-417.
  • 4Foley RN, Collins AJ. End-stage renal disease in the U- nited States: an update from the United States Renal Da- ta System [J]. J Am Soc Nephrol,2007,18 (10):2644- 2648.
  • 5Li H, Wei X, Wong MC, et al. A Cross-Sectional com- parison of perceived quality of primary care by hyperten- sive patients in Shanghai and Shenzhen, China [J]. Medicine, 2015,94(34) : e1388.
  • 6Liu X, Tosaki A, Engelman RM, et al. Reduction of postischaemic ventricular dysfunetion and arrhythmias by trapping hydroxyl radicals with salicylic acid[J]. Int J Tissue React, 1993,15 ( 1 ) : 25-30.
  • 7Minor RK, Baur JA, Gomes AP, et al. SRT1720 improves survival and heahhspan of obese mice [J]. Sci Rep,2011,1 (1):70.
  • 8Ichikawa T, Hayashi R, Suzuki K, et al. Sirtuin 1 acti- vator SRT1720 suppresses inflammation in an ovalbu- min-induced mouse model of asthma[Jl. Respirology, 2013,18(2) :332-339.
  • 9Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes [J]. Nature, 2007,450 (7170 ) : 712-716.
  • 10Ehauhan D, Bandi M, Singh AV, et al. Preclinical evalua- Lion of a novel SIRT1 modulator SRTI720 in multiple aayeloma cells[J]. Br J Haematol,2011,155(5) :588-598.

二级参考文献25

  • 1徐茵,张爱华,黄松明,沙玉根,郭梅,陈荣华.Nephrin在微小病变型肾病大鼠模型中的表达[J].南京医科大学学报(自然科学版),2005,25(4):217-220. 被引量:9
  • 2El BL,Rodrigues PR’Kuik DJ,et al. Nephrotic syndromein The Netherlands:a population-based cohort study anda review of the literature [J]. Pediatr Nephrol,2011,26(8):1241-1246.
  • 3Milne JC,Lambert PD,Schenk S,et al. Small molecule ac-tivators of SIRT1 as therapeutics for the treatment of type2diabetes[J]. Nature,2007,450(7170):712-716.
  • 4Minor RK,Baur JA,Gomes AP,et al. Erratum:CORRI-GENDUM :SRT1720 improves survival and healthspan ofobese mice[J]. Sci Rep,2011,1:70-79.
  • 5Chauhan D,Bandi M,Singh AV,et al. Preclinical evalu-ation of a novel SIRT1 modulator SRT1720 in multiplemyeloma cells [J]. BrJ Haematol,2011,155 (5):588-598.
  • 6Ichikawa T,Hayashi R,Suzuki K,et al. Sirtuin 1 activa-tor SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma [J]. Respirology,2013,18(2):332-339.
  • 7Yamazaki Y,Usui I,Kanatani Y,et al. Treatment withSRT1720,a SIRT1 activator,ameliorates fatty liver withreduced expression of lipogenic enzymes in MSG mice[J]. Am J Physiol Endocrinol Metab,2009,297 (5):E1179-E1186.
  • 8Funk JA,Odejinmi S,Schnellmann RG. SRT1720 inducesmitochondrial biogenesis and rescues mitochondrial func-tion after oxidant injury in renal proximal tubule cells[J]. JPharmacol Exp Ther,2010,333(2):593-601.
  • 9Asanuma K,Mundel P. The role of podocytes in glomeru-lar pathobiology[J]. Clin Exp Nephrol,2003,7(4):255-259.
  • 10Srivastava T,Sharma M,Yew KH,et al. LPS and PAN-in-duced podocyte injury in an in vitro model of minimalchange disease:changes in TLR profile[J]. J Cell CommunSignal,2012,7(1):49-60.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部